SHARE

Plandai Biotechnology Inc (OTCMKTS:PLPL) stated that for the three-month period completed March 31, 2015, the revenue jumped to $21,744 from $12,554 recorded in the same quarter, a year earlier. The sales constituted the revenue of timber from the tea estate businesses in South Africa. However, due to increases in expenses related to factory operations and other costs pertaining with operations of the Senteeko Tea Estate, there was a substantial increased in cost of sales, which surged from $141,046 to $181,214 in reported quarter.

Cannabis Science Inc (OTCMKTS:CBIS) Submits Initial Schedule 14C Filing

Cannabis Science Inc (OTCMKTS:CBIS) reported that it has submitted its initial Schedule 14C filing as the next measure to complete its dividend payout process of the previously submitted dividend share payout filed with the U.S. S.E.C. on August 18, 2011. The new application includes all of company’s shareholders in the landmark growth curve.

Cannabis Science has completed the preliminary step by submitting the initial statement with the new structure plan and no reverse split. The prime focus remains on enhancing shareholder value. As planned Cannabis Science apply for a new trading symbol to accommodate recently acquired financing that it has been negotiating to support all its drug development plans.

Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) Obtains $1.8 Million Grant

Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) reported that it obtained an award for a Fast Track SBIR grant of up to $1.8 million from the NCI, NIH, to support preclinical trials assessing the safety of intravenous injection of Tc99m tilmanocept, followed by a clinical trial offering the initial assessment of the efficacy and safety of SPECT imaging trials with IV Tc99m tilmanocept to quantify and identify both organ and skin related KS lesions in patients. This grant is divided in two parts with the first six month funding of $300,000 already been awarded. It will help company to finalize necessary collaborations and IRB approvals.

LEAVE A REPLY